UB GOOD

UB GOOD’s mix in May 2026 is split between Edible at 43.46% share and Vapor Pens at 42.56% share, while Tincture & Sublingual holds 8.27% and Capsules 4.98%, indicating a two-pillar portfolio where one category change can swing total outcomes. Vapor Pens expanded rapidly with 143.87% YoY and 15.72% MoM growth, outpacing Edible at 28.06% YoY and 2.20% MoM, while Capsules rose 62.22% YoY but fell 11.34% MoM and Concentrates contracted both YoY (-7.63%) and MoM (-38.27%). Average price edged up 0.88% YoY to $26.93 even as Edible priced at $26.16 and Vapor Pens at $25.66, suggesting mix rather than pricing drove the 59.51% YoY brand sales lift and that Edible’s rank at #2 in Ohio anchors visibility. The pattern implies UB GOOD’s near-equal weighting of Edible and Vapor Pens is now leverageable for volume comping, but shortfalls in Concentrates and a negative MoM in Capsules could cap upside if reliance on the two lead categories intensifies.

The pivot toward Vapor Pens (+143.87% YoY) alongside steadier Edible gains (+28.06% YoY) shifts UB GOOD from an Edible-led identity toward a dual-engine proposition, which supports broader basket reach but heightens exposure to vape volatility if MoM momentum (+15.72%) cools. With Edible ranked #2 in Ohio and brand-level sales up 59.51% YoY, the brand can trade customers between categories to smooth seasonality, yet the -11.34% MoM in Capsules and -38.27% MoM in Concentrates indicate gaps in wellness and dabbable formats that may limit share capture when those niches cycle up. The implication is to reinforce the Edible position while using the Vape surge to penetrate adjacent need states; otherwise, the current 43.46%/42.56% split could become a concentration risk rather than a hedge.